371 Progestogen Contraceptives Are Associated With an Increased Risk of Meningioma Development: A National Retrospective Cohort Analysis

View at publisher Summarise with VIRAT
Authors: Thaddeus D Harbaugh, Alexandra DiGiovanni, David R. Millar, Jason Sherman, Elias Rizk
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Recent studies have reported a modest but significant association between the use of progestogen contraceptives such as medroxyprogesterone acetate (MPA), and the development of meningiomas. Given that these contraceptives are widely used and increasingly prescribed, confirming their safety and associated risks is essential. Here, we retrospectively investigate this association on a national scale using TriNetX, a large electronic health record database. METHODS: TriNetX was used to identify female patients aged 12 years and older who had either taken MPA or who had never taken MPA or any other contraceptives. Propensity score-matching based on age yielded 456,276 patients in each cohort. Outcomes of interest included the development of unspecified meningiomas, as well as cerebral and spinal subtypes. Statistical tests were conducted on the TriNetX platform. Risk analysis was performed using chi-square tests for categorical variables, with computation of risk difference and risk ratio for each outcome. RESULTS: Patients who used MPA had a significantly higher risk of developing unspecified meningiomas (0.203%) compared to those not using MPA or any other contraceptives (0.126%) (risk ratio [RR] = 1.612, p < 0.0001). This increased risk was also observed for both cerebral (RR = 1.646, p < 0.0001) and spinal (RR = 1.704, p = 0.0261) subtypes of meningioma. CONCLUSIONS: We found that patients taking progestogens had a significantly increased risk of developing meningiomas, compared to those not using contraceptives. This lends further support to the hypothesis that progestogen contraceptives such as MPA may contribute to the development of meningioma. However, the absolute risk in both cohorts was exceptionally low, with fewer than 1% of patients diagnosed with a meningioma. Thus, future studies are necessary to confirm the mechanism underlying this association and to evaluate the safety of progestogen contraceptives, particularly regarding meningioma development.

Fields of Study & Subjects

Meningioma and schwannoma management Migraine and Headache Studies Reproductive Health and Contraception

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
101–101
Publication date
26 March 2026
Language
EN